Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug

Two weeks after MorphoSys filed for FDA review of its experimental treatment for a form of lymphoma, the company has struck a deal with Incyte to further develop and commercialize the therapy in the US and around the world.